Xoanacyl® (AVA1014) has been licensed from Akebia Therapeutics, Inc. in December 2022. Since then, Averoa has revised the clinical package and the regulatory strategy using all clinical studies and recent scientific publications to address the specific needs of the European market. The EMA filling is supported by 3 pivotal clinical studies performed by Keryx Biopharmaceuticals, a wholly owned subsidiary of Akebia Therapeutics Inc.
